Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer

European Journal of Clinical Pharmacology

Volumn 51, Issue 2, 1996, Pages 111-116

  Messori, A ^a   Becagli, P ^a   Trippoli, S ^a   Tendi, E ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Adjuvant chemotherapy; Breast cancer; Cost efectiveness analysis; Pharmacoeconomics

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUOROURACIL; METHOTREXATE; METOCLOPRAMIDE;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; COST BENEFIT ANALYSIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STATISTICS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; METHOTREXATE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 0029803177     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050169     Document Type: Article

References (19)

1. Mark DB, Hlatky MA, Califf RM, et al (1995) Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 332:1418-1424
2. Mark DB (1995) Economic analysis methods and end-points. In (Califf RM, Mark DB, Wagner B, Eds.): Acute coronary care in the thrombolytic era. Mosby. St. Louis, pp 167-182
3. Wong JB, Koff RS, Tine F, Pauker SG, (1995) Cost-effectiveness of interferon-alpha2B treatment for hepatitis B e antigenpositive chronic hepatitis B. Ann Intern Med 122:664-675
4. Lee ET (1980) Statistical methods for survival data analysis, Lifetime Learning Belmont
5. Varoli G (1990) Matematica Finanziaria. Patron, Bologna
6. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer - The results of 20 years of follow-up N Engl J Med 332:901-906
7. Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U (1977) The CMF program for operable breast cancer with positive axillary nodes. Cancer 39:2904-2915
8. Bonadonna G, Brusamolino E, Valagussa P, et al (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294:405-410
9. Messori A, Donati-Cori G, Tendi E (1983) Iterative least-squares fitting programs in pharmacokinetics for a programmable hand-held calculator. Am J Hosp Pharm 40:1673-1684
10. Ruffo S, Messori A, Donati-Cori G, et al (1985) Calculator programs for weighted least-squares nonlinear regression analysis in pharmacokinetics. Am J Hosp Pharm 42:628-629
11. Levitt M, Warr D, Yellec L, et al (1993) Ondansetron compared with dexametasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophospamide, methodtrexate, and fluorouracil. N Engl J Med 328: 1081-1084
12. Messori A (1996) Nuove tecniche di metanalisi e farmacoeconomia, Paper presented at the National Symposium "Metodologie per la Clinica" organised by the "Associazione Italiana Gastroenterologi Ospedalieri" and the "Associazione Italiana di Epidemiologia", Montecatini Terme, 18 19 Gennaio 1996, Italy
13. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
14. Robinson R (1993) Cost-effectiveness analysis. Br Med J 307: 793-795
15. Messori A, Brignola C, Trallori G, et al (1994) Effectiveness of 5-aminosalicyclic acid (5-ASA) for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 89:692-698
16. Messori A, Rampazzo R, Scroccaro G, et al (1995) Effectiveness of gabexate mesilate in acute pancreatitis:a meta-analysis. Dig Dis Sci 40:734-738
17. Messori A, Trippoli S, Tendi E (1996) G-CSF for the prophylaxis of neutropenic fever in patients with small-cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. J Clin Pharmacol Ther 21:57-63
18. Schulman KA, Lynn LA, Glick HA, Eisenberg JM (1991) Cost-effectiveness of low-dose zidovudibne therapy for asymptomatic patients with human immunodeficiency virus infection. Ann Intern Med 114:798-802
19. Rinaldi M, Bardelli F, Rampazzo R, Lusuriello P, Messori A (1995) Effectiveness of immunoglobulins for the prevention of systemic infections - A meta-analysis of 8 clinical studies in premature infants. Clin Drug Invest 10:328-336